US pharma giant Eli Lilly, Insilico Medicine secure deal worth $2.75 billion to bring AI-developed drugs to market
US pharmaceutical giant Eli Lilly has reached a deal worth $2.75 billion with Insilico Medicine. Under the agreement, Lilly will bring AI-developed drugs to the global market, while Insilico will receive $115 million upfront, with the remainder tied to regulatory approvals and commercial milestones
US pharmaceutical giant Eli Lilly has reached a deal worth $2.75 billion with Insilico Medicine. Under the agreement, Lilly will bring AI-developed drugs to the global market, while Insilico will receive $115 million upfront, with the remainder tied to regulatory approvals and commercial milestones
What's Your Reaction?
Economist Admin
Admin managing news updates, RSS feed curation, and PR content publishing. Focused on timely, accurate, and impactful information delivery.
